Therapeutic Advances in Medical Oncology

We're now on Bluesky! 🌟 Follow us for the latest in oncology research, expert insights, and journal updates—now across platforms. 🔗 Join us on Bluesky: bsky.app/profile/tamedo… #Oncology #CancerResearch #MedicalScience

🚨 Call for Papers! Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open. 🗓 Deadline: 6 Nov 2026 🔗 Submit here: buff.ly/sQgaDWS #Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer

Ther Adv Med Oncol: Second‑line mFOLFIRINOX outperformed SOX after gemcitabine+nab‑paclitaxel failure in advanced PDAC (n=113): • OS 10.4 vs 6.1 mo • PFS 4.8 vs 2.4 mo But with higher grade ≥3 AEs. 🔗buff.ly/QwPfnx9 #PancreaticCancer #GIOnc

🚨 Call for Papers! Ther Adv Med Onc invites submissions to our Special Collection on combined immunotherapy for advanced HCC. 🗓 Deadline: 30 Oct 2026 🔗 Submit: buff.ly/e8XA6kU #HCC #LiverCancer #Immunotherapy #Oncology

Ther Adv Med Oncol: A rev highlights maintenance therapy as a strategy to extend benefit after first‑line anthracyclines in advanced soft tissue #sarcoma. PLD emerges as a promising continuation option with reduced cardiotoxicity. 🔗buff.ly/tV2uyCE #STS #Oncology

📣 Call for Papers Novel Approaches to High‑Risk HER2+ Early‑Stage Breast Cancer - a new Special Collection in Therapeutic Advances in Medical Oncology - is now open. 🗓 Deadline: 4 Dec 2026 🔗 buff.ly/3jv7zmw

⬇️ shows #CLDN18.2 expression does not influence outcomes of 1L immunochemotherapy in HER2-, pMMR, PD‑L1 CPS≥1 metastatic #gastric/GEJ cancer. Findings align with recent studies showing no OS/PFS differences by CLDN18.2 status. @sagepub_japan 🔗 buff.ly/rdAewUh

Call for Papers.Special Collection: Precision Immuno‑Oncology We welcome clinical trials, reviews, and real‑world evidence shaping precision cancer care. Guest Editor: @PengL_Robin 🔗 Submission details: buff.ly/fqWNKby #ImmunoOncology #PrecisionMedicine #CancerResearch

A rev in Ther Adv Med Onc highlights the unique challenges of early #BreastCancer in young BRCA carriers-covering surveillance, risk‑reducing surgery, PARP‑based therapy, fertility considerations, and survivorship needs. 🔗buff.ly/6fj4pvT #BRCA #Oncology #YoungPatients

Gain valuable insights from a new article published in Therapeutic Advances in Medical Oncology by the cancer center’s Lisa M. Landrum, MD, PhD, and colleagues. Learn more: ow.ly/VkLm50XIxbN. #ResearchCuresCancer #NCIcomprehensive @TAMedOncol

A rev in Ther Adv Med Onc summarizes major advances in SCLC: chemo‑IO as standard in ES‑SCLC, durvalumab approved for LS‑SCLC, emerging options for relapse (lurbinectedin, tarlatamab), and evolving biomarkers/transcriptional subtypes. 🔗buff.ly/LoHtjYT #SCLC #LungCancer

Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗buff.ly/dOq2XvY #PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics

Investigate & optimize hematologic parameters before PARPi (ideal Hb ≥10 g/dL). Monitor during first 3 months (every 15 days; more often if high‑risk). Hold PARPi for G2-3 anemia, thrombocytopenia, or G3 neutropenia. Watch for persistent cytopenias >4 weeks → consider MDS/AML.

French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need. 🔗 Full article: buff.ly/9fa08rG #ProstateCancer #mCRPC #PARPInhibitors #Oncology

ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC. @Hiroki_Osumi @sagepub_japan 🔗buff.ly/S2kBuFe #GastricCancer #HER2 #ctDNA

Real‑world, 8‑year multicancer study of lenvatinib shows manageable long‑term use across DTC, AdCC, HCC & EC. Notably, BMI declined during treatment (p=0.045), highlighting the need for closer monitoring in low‑BMI patients. 🔗 buff.ly/Ckygpuz #Lenvatinib @elenacolomboMD

Review on pregnancy & breast cancer in young women: PrBC vs PPBC distinctions, chemo during pregnancy (incl. taxanes after 1st trimester), POSITIVE trial on ET interruption, and fertility preservation gaps for targeted agents. 🔗 buff.ly/ZDZelh2 #BreastCancer #YWBC

More evidence that #immunotherapy works better in the morning. In a prospective, randomized phase III trial, giving first-line chemo-immunotherapy earlier in the day (<15:00) nearly doubled PFS (11.3 vs 5.7 mo, HR 0.40) and improved OS (28.0 vs 16.8 mo; HR 0.42) in advanced NSCLC. More effective, no added cost and easy to implement. Likely reflects circadian immune rhythms with greater CD8⁺ activation and less T-cell exhaustion. doi.org/10.1038/s41591… @OncoAlert

Review: Histologic transformation is a key mechanism of resistance in driver‑positive NSCLC, leading to aggressive SCLC, squamous, or neuroendocrine phenotypes.⬇️ summarize mechanisms and treatment options. 🔗 buff.ly/jJq7xOQ #NSCLC #LungCancer #Oncology #TargetedTherapy

Among 2798 pts, treatment duration was longer with combinations in both age groups (young 4.1 vs 2.4 mo; elderly 3.9 vs 2.1 mo). TEAEs were similar (≈78%). Leading TRAEs: PPES and hypertension-varying slightly by age group. Overall: fruquintinib remains a safe option across ages

A Phase IV real‑world analysis examined fruquintinib safety in two under‑studied CRC populations in China: young adults (<50) and the late‑elderly (≥75). Safety events were comparable between age groups, supporting broad applicability. buff.ly/1Wpdefh #ColorectalCancer